BMO Capital Markets Lowers Alnylam Pharmaceuticals (ALNY) Price Target to $124.00

Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price reduced by BMO Capital Markets from $125.00 to $124.00 in a report issued on Tuesday morning. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on ALNY. BidaskClub cut Alnylam Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, June 18th. ValuEngine cut Alnylam Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday, June 21st. Piper Jaffray Companies decreased their price objective on Alnylam Pharmaceuticals from $182.00 to $160.00 and set an overweight rating for the company in a report on Wednesday, June 27th. Zacks Investment Research cut Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 4th. Finally, Cowen restated a buy rating and issued a $157.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, August 2nd. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $144.17.

ALNY opened at $76.65 on Tuesday. Alnylam Pharmaceuticals has a 1 year low of $76.29 and a 1 year high of $153.99. The stock has a market capitalization of $7.91 billion, a price-to-earnings ratio of -14.14 and a beta of 2.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.22 and a current ratio of 13.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The firm had revenue of $29.91 million for the quarter, compared to the consensus estimate of $16.96 million. During the same quarter last year, the business posted ($1.07) EPS. The company’s revenue for the quarter was up 87.8% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals will post -7.28 EPS for the current fiscal year.

In related news, COO Yvonne Greenstreet sold 2,500 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief operating officer now owns 1,916 shares in the company, valued at $229,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Maraganore sold 50,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, July 25th. The stock was sold at an average price of $105.39, for a total value of $5,269,500.00. Following the transaction, the chief executive officer now owns 201,297 shares of the company’s stock, valued at approximately $21,214,690.83. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of ALNY. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $137,000. Mutual of America Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 98.5% during the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after purchasing an additional 960 shares during the period. IPG Investment Advisors LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $217,000. First Republic Investment Management Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $230,000. Finally, Riverhead Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 195.6% during the second quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares during the period. Institutional investors and hedge funds own 90.05% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

See Also: Trading Penny Stocks

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WPP  – Analysts’ Weekly Ratings Changes
WPP – Analysts’ Weekly Ratings Changes
Rotork  Upgraded at Credit Suisse Group
Rotork Upgraded at Credit Suisse Group
Hollywood Bowl Group  Stock Rating Reaffirmed by Peel Hunt
Hollywood Bowl Group Stock Rating Reaffirmed by Peel Hunt
Ted Baker  PT Lowered to GBX 2,000 at Goldman Sachs Group
Ted Baker PT Lowered to GBX 2,000 at Goldman Sachs Group
TIM Participacoes  Upgraded by Zacks Investment Research to “Hold”
TIM Participacoes Upgraded by Zacks Investment Research to “Hold”
Home Depot  versus Jewett-Cameron Trading  Critical Survey
Home Depot versus Jewett-Cameron Trading Critical Survey


© 2006-2018 Ticker Report